You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
金城醫藥(300233.SZ):子公司泊沙康唑腸溶片和注射用頭孢唑肟鈉獲批
格隆匯 06-05 17:48

格隆匯6月5日丨金城醫藥(300233.SZ)公佈,公司全資子公司北京金城泰爾製藥有限公司及控股子公司廣東金城金素製藥有限公司分別收到國家藥品監督管理局下發的泊沙康唑腸溶片和注射用頭孢唑肟鈉《藥品註冊證書》。

泊沙康唑腸溶片是一種第二代三唑類抗真菌藥物,用於治療侵襲性麴黴病和預防侵襲性麴黴菌和念珠菌感染,具有抗菌譜廣、抗菌活性高、安全耐受性好等優勢。

注射用頭孢唑肟鈉適用於治療敏感菌所致的下呼吸道感染、尿路感染、腹腔感染、盆腔感染、敗血症、皮膚軟組織感染、骨和關節感染;肺炎鏈球菌或流感嗜血桿菌所致腦膜炎和單純性淋病。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account